CL2014002789A1 - Terapia de combinación de anticuerpos anti-mif y glucocorticoides - Google Patents

Terapia de combinación de anticuerpos anti-mif y glucocorticoides

Info

Publication number
CL2014002789A1
CL2014002789A1 CL2014002789A CL2014002789A CL2014002789A1 CL 2014002789 A1 CL2014002789 A1 CL 2014002789A1 CL 2014002789 A CL2014002789 A CL 2014002789A CL 2014002789 A CL2014002789 A CL 2014002789A CL 2014002789 A1 CL2014002789 A1 CL 2014002789A1
Authority
CL
Chile
Prior art keywords
mif
glucocorticoid
antibodies
combination therapy
therapy
Prior art date
Application number
CL2014002789A
Other languages
English (en)
Inventor
Randolf Kerschabaumer
Dirk Voelkel
Friedrich Scheiflinger
Hartmut Ahrlich
Original Assignee
Baxter Healthcare Sa
Baxter Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48190488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002789(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Healthcare Sa, Baxter Int filed Critical Baxter Healthcare Sa
Publication of CL2014002789A1 publication Critical patent/CL2014002789A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CL2014002789A 2012-04-16 2014-10-16 Terapia de combinación de anticuerpos anti-mif y glucocorticoides CL2014002789A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261624988P 2012-04-16 2012-04-16
US201261668864P 2012-07-06 2012-07-06
US201361785626P 2013-03-14 2013-03-14

Publications (1)

Publication Number Publication Date
CL2014002789A1 true CL2014002789A1 (es) 2014-12-12

Family

ID=48190488

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014002789A CL2014002789A1 (es) 2012-04-16 2014-10-16 Terapia de combinación de anticuerpos anti-mif y glucocorticoides

Country Status (17)

Country Link
US (3) US20150250873A1 (es)
EP (1) EP2838559B1 (es)
JP (1) JP6236062B2 (es)
KR (1) KR20150008105A (es)
CN (1) CN104470540B (es)
AU (2) AU2013203957B9 (es)
CA (1) CA2869987A1 (es)
CL (1) CL2014002789A1 (es)
ES (1) ES2779036T3 (es)
HK (1) HK1206984A1 (es)
IL (1) IL235037A0 (es)
MX (1) MX2014012534A (es)
NZ (1) NZ628454A (es)
PL (1) PL2838559T3 (es)
RU (1) RU2014145694A (es)
WO (1) WO2013156472A1 (es)
ZA (1) ZA201507929B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150029017A (ko) 2012-07-10 2015-03-17 박스터 헬쓰케어 에스에이 항-mif 면역조직화학
US9688635B2 (en) 2012-09-24 2017-06-27 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN106068456A (zh) * 2014-01-03 2016-11-02 百深有限责任公司 抗‑mif免疫组织化学
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
EP3802595A1 (en) * 2018-06-07 2021-04-14 OncoOne Research & Development GmbH Anti-oxmif/anti-cd3 antibody for cancer treatment
EP4069735A1 (en) * 2019-12-06 2022-10-12 OncoOne Research & Development GmbH Anti-oxmif/anti-cd3 bispecific antibody constructs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4708510B2 (ja) * 1993-05-17 2011-06-22 サイトカイン ファーマサイエンシズ,インコーポレーテッド サイトカイン媒介毒性に関係する疾患の治療における遊走阻止因子の抑制
US6645493B1 (en) * 1993-05-17 2003-11-11 The Picower Institute For Medical Research Composition containing anti-MIF antibody
WO2001064749A2 (en) * 2000-02-28 2001-09-07 Idec Pharmaceuticals Corporation Method for preparing anti-mif antibodies
US7205107B2 (en) * 2001-12-21 2007-04-17 Cytokine Pharmasciences, Inc. Macrophage migration inhibitory factor (MIF) promoter polymorphism in inflammatory disease
US20070213296A1 (en) * 2006-03-07 2007-09-13 Yanzhen Zhang Compositions and methods for the treatment of immunoinflammatory disorders
CN100457895C (zh) * 2006-05-24 2009-02-04 中国科学院生物物理研究所 鼠抗人巨噬细胞迁移抑制因子单克隆抗体及其应用
US20080287406A1 (en) * 2007-03-26 2008-11-20 Lessem Jan N Compositions and methods for treating medical conditions
US20090220521A1 (en) * 2008-01-04 2009-09-03 Randolf Kerschbaumer Anti MIF Antibodies

Also Published As

Publication number Publication date
HK1206984A1 (en) 2016-01-22
WO2013156472A1 (en) 2013-10-24
AU2013203957B9 (en) 2015-10-15
CN104470540B (zh) 2016-08-31
JP6236062B2 (ja) 2017-11-22
AU2013203957A1 (en) 2013-10-31
AU2013203957B2 (en) 2015-09-03
CN104470540A (zh) 2015-03-25
ES2779036T3 (es) 2020-08-13
EP2838559B1 (en) 2019-11-27
CA2869987A1 (en) 2013-10-24
ZA201507929B (en) 2017-11-29
EP2838559A1 (en) 2015-02-25
IL235037A0 (en) 2014-12-31
MX2014012534A (es) 2014-11-21
US20180280501A1 (en) 2018-10-04
NZ628454A (en) 2015-10-30
JP2015514734A (ja) 2015-05-21
KR20150008105A (ko) 2015-01-21
US20150250873A1 (en) 2015-09-10
PL2838559T3 (pl) 2020-06-01
AU2015210447B2 (en) 2016-10-20
US20210187105A1 (en) 2021-06-24
AU2015210447A1 (en) 2015-09-03
RU2014145694A (ru) 2016-06-10

Similar Documents

Publication Publication Date Title
CL2015001321A1 (es) Anticuerpos anti-ceacam5 y usos de éstos
PL3978522T3 (pl) Ludzkie przeciwciała przeciwko fel d1 i sposoby ich stosowania
DK2806892T3 (da) Kombineret terapeutisk anvendelse af antistoffer og endoglycosidaser
PL2812443T3 (pl) Przeciwciała CD47 i sposoby ich zastosowania
PL2922850T3 (pl) Związki i sposoby ich stosowania
IL263320A (en) Anti-hemagglutinin antibodies and methods of use
CO7000747A2 (es) Anticuerpos anti-lrp5 y métodos de uso
ZA201501858B (en) Anti-mcam antibodies and associated methods of use
BR112014028366A2 (pt) anticorpos anti-ly6e e imunoconjugados e métodos de uso
SI2858671T1 (sl) Formulacija protiteles
EP2930714A4 (en) Singing voice synthesizing system and singing voice synthesizing method
IL227465B (en) Blockstent device amd methods of use
EA201892584A1 (ru) Системы и способы для изготовления объемных непрерывных волокон
LT2885010T (lt) Tautopatijos gydymo būdai
EP2870180C0 (en) ANTI-BIOTIN ANTIBODIES AND METHODS OF USE
EP3470433C0 (en) MODIFIED ANTIBODY REGIONS AND THEIR USES
SG11201502757QA (en) Anti-c16orf54 antibodies and methods of use thereof
EP2925890C0 (en) ACCELERATED PREDICTION OF CANCER PROGRESSION AND RESPONSE TO TREATMENT
IL234606B (en) Novel methods and composition for treatment of disease
IL262252B (en) Therapeutic compositions and methods involving mrna transfection
CL2014002789A1 (es) Terapia de combinación de anticuerpos anti-mif y glucocorticoides
IL233875A (en) Composition and use thereof in the treatment of anal rhagades
PT3228313T (pt) Formas de dosagem e utilizações terapêuticas de l-4-cloroquinurenina
CL2016001327A1 (es) Terapia de combinación de anticuerpos anti-mif y quimioterapeuticos (divisional de solicitud 2788-14)
EP2811295A4 (en) SEPARATION AGENT AND METHOD FOR MANUFACTURING SAME